Corvus 制药
CRVS
9.52
-0.33
-3.35%
Corvus 制药
US · CRVS
#3339 按市值排名
上市于 2016
9.52
-0.33
-3.35%
实时 - 追踪5344个代码 - 心跳于512秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了1.4个百分点。
机构持股
- 机构持股比例
- 86.41% -1.42pp
- 机构数量
- 202 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund40.59%
VC/PE Fund27.14%
Hedge Fund11.09%
Public Company4.99%
Individual/Insider3.54%
Private Company1.90%
Insurance Company0.39%
Government Pension Fund0.25%
Other10.06%
主要股东 截至 2026-06-30
OrbiMed Advisors LLC
8.52% · 7.17M 股
BlackRock
8.49% · 7.14M 股
State Street Global Advisors
5.32% · 4.47M 股
Vanguard Capital Management, LLC
4.53% · 3.81M 股
T. Rowe Price Group, Inc.
4.50% · 3.79M 股
Adams Street Partners, LLC
3.89% · 3.28M 股
Vivo Capital, LLC
3.34% · 2.81M 股
Wellington Management Group
3.25% · 2.73M 股
Perceptive Advisors LLC
3.17% · 2.67M 股
Deep Track Capital, LP
2.96% · 2.49M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 47次买入 · 2次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Miller | Co-Founder, President, CEO & Chairman of the Board | 2.77% |
| Leiv Lea | Chief Financial Officer | 0.34% |
| William Jones | Senior Vice President of Pharmaceutical Development | 0.21% |
| Richard van den Broek | Director | 0.19% |
| David Moore | Director | 0.03% |
| Linda Grais | Independent Director | 0.01% |
| OrbiMed Advisors LLC | -- | -- |
| Ian T. Clark | Independent Director | -- |
| Peter Thompson | Co-Founder & Independent Director | -- |
| Scott William Morrison | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-10 | Richard van den Broek | Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | David Moore | Director | Open Market Acquisition | +21,700 | $11.53 |
| 2026-06-10 | David Moore | Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-05-17 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Open Market Acquisition | +6,932 | $12.01–12.05 |
| 2026-01-27 | Peter Thompson | Co-Founder & Independent Director | Derivative Exercise and Retained | +210,000 | $0.97–15.00 |
| 2025-12-03 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Other Derivative Acquisition | +1,000,000 | $8.81 |
| 2025-12-03 | Leiv Lea | Chief Financial Officer | Other Derivative Acquisition | +400,000 | $8.81 |
| 2025-12-03 | Jeffrey Arcara | Chief Business Officer | Other Derivative Acquisition | +100,000 | $8.81 |
| 2025-12-03 | William Jones | Senior Vice President of Pharmaceutical Development | Other Derivative Acquisition | +400,000 | $8.81 |
| 2025-10-01 | David Moore | Director | Other Derivative Acquisition | +30,000 | $7.04 |
| 2025-06-26 | OrbiMed Advisors LLC | -- | Derivative Exercise and Sale | -1,176,332 | $3.50–4.16 |
| 2025-06-26 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +221,352 | $3.50 |
| 2025-06-11 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-03 | William Jones | Senior Vice President of Pharmaceutical Development | Derivative Exercise and Retained | +19,357 | $3.50 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Corvus 制药 讨论区 0 条评论